NYSE · TMO
Thermo Fisher Scientific Inc.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
Loading market information…
NASDAQ · ME · USD
Stock price, earnings
Quote as of Mar 9, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
23andMe Holding Co.’s quoted price sits in the lower half of its reported 52-week range, 95.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow 23andMe Holding Co.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $44.75M-17.18% vs estimate |
| Q2 2023 | Nov 8, 2023 | -$3.20-2,185.71% vs estimate | $50.00M-11.97% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$236.94+$2.87 (+1.23%)
Danaher Corporation’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$181.15-$0.33 (-0.18%)
Agilent Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.01% below the high.
$480.07+$3.19 (+0.67%)
Waters Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.46% below the high.
$575.98+$13.07 (+2.32%)
IDEXX Laboratories, Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.2% below the high.
$290.06+$1.27 (+0.44%)
Illumina, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.24% below the high.
$185.31+$2.72 (+1.49%)
Guardant Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.0% below the high.
$173.45$0.00 (0.0%)
Twist Bioscience Corporation’s quoted price sits in the upper half of its reported 52-week range, 21.06% below the high.
